Primaquine for malaria, vivax

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 2 Jun 2020: Trial registered, NCT04411836
  2. 25 Apr 2021: Trial started, NCT04411836
  3. 28 Nov 2023: Trial registered, NCT06148792
  4. 10 May 2024: Trial started, NCT06148792

The trials

NCT04411836: Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

State
Completed
Phase
Phase 3
People
960 taking part
Started
25 Apr 2021
Primary completion
30 Sep 2024
Arms
PQ Intervention
Results
None posted
Papers
doi:10.1016/s1473-3099(25)00729-7, doi:10.1136/bmjopen-2026-119698
  1. 2 Jun 2020: Trial registered
  2. 25 Apr 2021: Trial started
  3. 30 Sep 2024: Trial completed

NCT06148792: A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

State
Under way
Phase
Phase 3
People
1,090 planned
Started
10 May 2024
Primary completion
1 Mar 2027
Arms
PQ7
Results
None posted
  1. 28 Nov 2023: Trial registered
  2. 10 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Kanaprim, Maliride, Neo-quipenyl.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.